Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Joe Copia's daytrades/investments and thoughts -- Ignore unavailable to you. Want to Upgrade?

To: Whiskeyj who wrote (14126)	4/6/1999 12:22:00 PM
From: Joe Copia	Respond to of 25711

Great for JVWB! Added BICO for a hold until the FDA approves its Diasensor Monday March 29, 11:05 am Eastern Time Company Press Release Biocontrol Delivers Diasensor 1000 to the FDA PITTSBURGH--(BUSINESS WIRE)--March 29, 1999--Biocontrol Technology Inc. (OTC BB:BICO - news) announced today that a Diasensor 1000 Noninvasive Blood Glucose Monitor was delivered to the Food and Drug Administration (FDA) following the conclusion of a technical seminar presented to FDA staff members at the Company's Indiana, Pa., facilities on March 23 and 24, 1999. The FDA purchased the Diasensor 1000, which is already approved for sale in the 15-country European Union, in order to evaluate its performance characteristics and conduct laboratory and clinical research on noninvasive monitoring. The purpose of the seminar was to educate the attending FDA staff members regarding the application, operation and maintenance of the device. Biocontrol will continue to assist the FDA, as requested, in their study of this new noninvasive technology. David L. Purdy, president of Biocontrol, stated, ''The FDA personnel who attended the seminar were very knowledgeable about existing invasive glucose testing technology, and the Biocontrol presentation was designed to extend FDA personnel's understanding of the Company's noninvasive technology used in the Diasensor 1000. Both the FDA and Biocontrol personnel profited from the interchange of concepts embodied in the Diasensor.'' Biocontrol Technology has its corporate offices in Pittsburgh, Pa., and is involved in the development and manufacture of biomedical devices and environmental products. Biocontrol has the exclusive rights to the research and development and manufacturing of the Diasensor 1000. Subsidiary Diasensor.com Inc., also located in Pittsburgh, Pa., owns the patent, marketing and distribution rights to the sensor. WEB SITE: bico.com INVESTOR RELATIONS NEWSLINE NUMBER: 800/357-6204 Contact: Biocontrol Technology Inc., Pittsburgh Investors: Diane McQuaide, 412/429-0673 or Media: Susan Taylor, 412/429-0673